Canada - English - Health Canada

pharmascience inc - apremilast; apremilast; apremilast - tablet - 10mg; 20mg; 30mg - apremilast 10mg; apremilast 20mg; apremilast 30mg

Canada - English - Health Canada

apotex inc - apremilast; apremilast; apremilast - tablet - 10mg; 20mg; 30mg - apremilast 10mg; apremilast 20mg; apremilast 30mg

Canada - English - Health Canada

glenmark pharmaceuticals canada inc. - apremilast; apremilast; apremilast - tablet - 10mg; 20mg; 30mg - apremilast 10mg; apremilast 20mg; apremilast 30mg

Canada - English - Health Canada

marcan pharmaceuticals inc - apremilast; apremilast; apremilast - tablet - 10mg; 20mg; 30mg - apremilast 10mg; apremilast 20mg; apremilast 30mg

Canada - English - Health Canada

auro pharma inc - apremilast; apremilast; apremilast - tablet - 10mg; 20mg; 30mg - apremilast 10mg; apremilast 20mg; apremilast 30mg

Canada - English - Health Canada

auro pharma inc - apremilast; apremilast; apremilast - tablet - 10mg; 20mg; 30mg - apremilast 10mg; apremilast 20mg; apremilast 30mg

Canada - English - Health Canada

teva canada limited - apremilast; apremilast; apremilast - tablet - 10mg; 20mg; 30mg - apremilast 10mg; apremilast 20mg; apremilast 30mg

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - apremilast (unii: up7qbp99pn) (apremilast - unii:up7qbp99pn) - apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. apremilast tablets are contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation [see adverse reactions (6.1)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to apremilast during pregnancy. information about the registry can be obtained by calling 1-877-311-8972. risk summary available pharmacovigilance data with apremilast use in pregnant women have not established a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes, but these data are extremely limited. based on findings from animal reproduction studies, apremilast may increase the risk for fetal loss. in animal embryo-fetal development studies, the administration of apremilast to pregnant cynomolgus monkeys during orga

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - apremilast (unii: up7qbp99pn) (apremilast - unii:up7qbp99pn) - apremilast tablets are indicated for the treatment of adult patients with active psoriatic arthritis. apremilast tablets are contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation [see adverse reactions ( 6.1)].  risk summary  available pharmacovigilance data with apremilast use in pregnant women have not established a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes, but these data are extremely limited. based on findings from animal reproduction studies, apremilast may increase the risk for fetal loss. in animal embryo-fetal development studies, the administration of apremilast to pregnant cynomolgus monkeys during organogenesis resulted in dose-related increases in abortion/embryo-fetal death at dose exposures 2.1-times the maximum recommended human therapeutic dose (mrhd) and no adverse effect at an exposure of 1.4-times the mrhd. when administered to pregnant mice, during organo

Canada - English - Health Canada

pharmascience inc - apremilast - tablet - 30mg - apremilast 30mg